Certain fungal skin infections are becoming resistant to terbinafine, a common antifungal medication, due to genetic mutations in an enzyme called squalene epoxidase. Using computer models and analysis tools, researchers identified which mutations most strongly reduce the drug’s effectiveness and where the protein changes occur. Four specific mutations were found to prevent terbinafine from binding to its target, offering insights that could help develop better antifungal treatments.